Bristol-Myers Squibb Shows Improved Relative Strength; Still Shy Of BenchmarkInvestors Business Daily • 07/20/20
Is Bristol Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "Zacks Investment Research • 07/17/20
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)Business Wire • 07/17/20
Bristol Myers Squibb Announces Expiration and Final Results of Registered Exchange OffersBusiness Wire • 07/16/20
These 3 Patient Advocacy Groups Are Helping Solve Issues in the COVID-19 PandemicThe Motley Fool • 07/12/20
Bristol Myers (BMY) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 07/09/20
Bristol Myers Just Launched A New MS Drug — But Is BMY Stock A Buy?Investors Business Daily • 07/08/20
Bristol Myers Squibb: Insider Anticipating Significant Shareholder Value Creation From MergerSeeking Alpha • 07/02/20
Q2 Earnings Will Be Gruesome and COVID Is Back: Rotate to Defensive Dividend Stocks24/7 Wall Street • 07/02/20